Generate Biomedicines, Inc. (GENB) vs Intellia Therapeutics, Inc. (NTLA)
A side-by-side comparison of Generate Biomedicines, Inc. and Intellia Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GENB
Generate Biomedicines, Inc.
$13.69HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
NTLA
Intellia Therapeutics, Inc.
$12.74HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — GENB vs NTLA
growth of $100 · dividends reinvested · last 1yGENB +10.0% (+10.0%/yr)NTLA -7.5% (-7.5%/yr)GENB compounded faster over this window
GENB NTLA
GENB vs NTLA: by the numbers
- •NTLA is the larger company ($1.78B vs $1.75B market cap).
- •Both run net losses; GENB's is the smaller (-636.99% vs -672.16% net margin).
Metrics side by side
Valuation
| Metric | GENB | NTLA |
|---|---|---|
| P/S ratio | N/A | 29.91 |
| P/B ratio | 3.85 | 2.45 |
Profitability
| Metric | GENB | NTLA |
|---|---|---|
| Gross margin | 100.00% | 76.47% |
| Operating margin | -737.04% | -651.67% |
| Net margin | -636.99% | -672.16% |
| ROE | N/A | -54.96% |
| ROIC | -94.79% | -54.45% |
Growth (annualized)
| Metric | GENB | NTLA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.31% |
| Total return CAGR (5Y) | N/A | -37.13% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.